Compare APC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APC | ABUS |
|---|---|---|
| Founded | 2025 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 892.9M | 1.0B |
| IPO Year | 2025 | 2008 |
| Metric | APC | ABUS |
|---|---|---|
| Price | $18.67 | $5.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $21.75 | $5.00 |
| AVG Volume (30 Days) | 136.5K | ★ 4.8M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 10.99% | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | 0.46 | ★ 0.84 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $4.47 | N/A |
| Revenue Next Year | $4.20 | $239.71 |
| P/E Ratio | $41.13 | ★ $6.10 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $17.08 | $3.50 |
| 52 Week High | $21.72 | $5.45 |
| Indicator | APC | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 59.88 |
| Support Level | $17.81 | $4.99 |
| Resistance Level | $19.70 | $5.42 |
| Average True Range (ATR) | 0.45 | 0.08 |
| MACD | 0.11 | -0.02 |
| Stochastic Oscillator | 88.97 | 45.90 |
Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.